EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Reactivation after total thyroidectomy? A thyroid eye disease case that challenges established clinical paradigms

Alejandra Niño Alarcón iD, Diana Cristina Henao, Leonardo Rojas, Ana María Gomez, Yeimer Ortiz Martínez

Endocrinology, Diabetes & Metabolism Case Reports · 01.04.2026 · 2026 (2)

DOI: 10.1530/edm-25-0173 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, online erschienen am 09.06.2026. Verfasst von Alejandra Niño Alarcón und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves’ disease, with an incidence of approximately 1.9 cases per 10,000 inhabitants per year. Its pathophysiology involves an autoimmune response mediated by TSH receptor antibodies (TRAbs), leading to inflammation, fibroblast activation, and orbital tissue remodeling. Although TED typically becomes inactive within 1–3 years, 5–10% of patients experience recurrences. Persistence or reactivation after total thyroidectomy is uncommon, and published reports remain limited. We report a 56-year-old man with Graves’ disease diagnosed in 2020 and multiple TED reactivations treated with intravenous methylprednisolone. In 2022, he was diagnosed with low-risk papillary thyroid carcinoma (T1a N0 M0) and underwent total thyroidectomy; radioiodine therapy was withheld due to orbitopathy. Despite complete surgery, he developed a new reactivation in November 2023. In March 2025, he presented with ocular pain; active TED was confirmed with a CAS of 6/7 and moderate-to-severe EUGOGO classification. Laboratory tests revealed positive TRAbs and suppressed TSH. A multidisciplinary team recommended another steroid course followed by tocilizumab. TED reactivation after thyroidectomy is rare and challenges the rationale of antigen removal. Possible mechanisms include microscopic residual thyroid tissue or persistent TRAb activity. Similar reports are limited, and this appears to be the first case described in Colombia. This case highlights the need for multidisciplinary management and the potential role of immunomodulators such as tocilizumab in refractory post-thyroidectomy TED. Further research is needed to clarify factors contributing to disease persistence. Learning points

Schlagwörter

Stichwörter der Autor:innen

immunotherapyinflammationthyroidthyroid eye disease

Autor:innen und Institutionen

  • Internal Medicine Department, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.
  • Endocrinology Department, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.

ORCID-Profile: Alejandra Niño Alarcón

Zitieren

APA

Niño Alarcón, A., Henao, D. C., Rojas, L., Gomez, A. M., & Ortiz Martínez, Y. (2026). Reactivation after total thyroidectomy? A thyroid eye disease case that challenges established clinical paradigms. Endocrinology, Diabetes & Metabolism Case Reports, 2026(2). https://doi.org/10.1530/edm-25-0173

Vancouver

Niño Alarcón A, Henao DC, Rojas L, Gomez AM, Ortiz Martínez Y. Reactivation after total thyroidectomy? A thyroid eye disease case that challenges established clinical paradigms. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(2). doi:10.1530/edm-25-0173

BibTeX
@article{NioAlarcn2026,
  author = {Niño Alarcón, Alejandra and Henao, Diana Cristina and Rojas, Leonardo and Gomez, Ana María and Ortiz Martínez, Yeimer},
  title = {Reactivation after total thyroidectomy? A thyroid eye disease case that challenges established clinical paradigms},
  journal = {Endocrinology, Diabetes & Metabolism Case Reports},
  year = {2026},
  volume = {2026},
  number = {2},
  doi = {10.1530/edm-25-0173}
}
Kostenlos starten →